Keyphrases
Atrial Fibrillation
100%
Warfarin
45%
Rivaroxaban
34%
Non-valvular Atrial Fibrillation
29%
Stroke Prevention
25%
Antithrombotic Therapy
17%
Confidence Interval
16%
Vitamin K Antagonists
15%
Anticoagulation
15%
ROCKET-AF
13%
Bleeding
12%
Rocket
12%
Stroke Risk
12%
Thromboembolism
11%
Aspirin
11%
Dabigatran
10%
High Risk
10%
Hazard Ratio
9%
Systemic Embolism
9%
GLORIA
9%
Embolism
9%
Major Bleeding
8%
Non-vitamin K Antagonist Oral Anticoagulants
8%
Once-daily
8%
Factor Xa Inhibitors
8%
Stroke Prevention in Atrial Fibrillation
7%
Vitamin K
7%
Ischemic Stroke
7%
Anticoagulants
7%
Antagonism
7%
Direct Factors
7%
Percutaneous Coronary Intervention
7%
Clinical Trials
7%
Risk Factors
6%
International Normalized Ratio
6%
Bleeding Risk
6%
Venous Thromboembolism
6%
Transient Ischemic Attack
5%
Novel Oral Anticoagulants
5%
Anticoagulant Therapy
5%
Randomized Trial
5%
Heart Failure
5%
Clinically Significant
5%
Oral Anticoagulation
5%
Oral Anticoagulants
5%
Myocardial Infarction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
84%
Cerebrovascular Accident
47%
Warfarin
39%
Rivaroxaban
34%
Anticoagulant Agent
26%
Bleeding
19%
Antivitamin K
16%
Thromboembolism
10%
Congestive Heart Failure
10%
Acetylsalicylic Acid
8%
Dabigatran
8%
Antiplatelet
7%
Blood Clotting Factor 10a
7%
Clinical Trial
7%
Venous Thromboembolism
7%
Antithrombotic Therapy
6%
Vitamin K Group
6%
Disease
6%
Medicine and Dentistry
Atrial Fibrillation
71%
Apoplexy
43%
Antithrombotic
20%
Anticoagulation
15%
Warfarin
15%
Thromboembolism
12%
Rivaroxaban
11%
Vitamin K Antagonist
9%
Congestive Heart Failure
9%
Antithrombotic Therapy
9%
Bleeding
8%
Cardiovascular System
7%
Disease
6%
Brain Ischemia
6%
Acetylsalicylic Acid
5%
Hazard Ratio
5%